Accelerating HIV-1 vaccine efficacy trials

Dan H. Barouch; Nelson L. Michael

doi:10.1016/j.cell.2014.10.046

Accelerating HIV-1 vaccine efficacy trials

Dan H. Barouch^*, Nelson L. Michael

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

14 Scopus citations

Abstract

Despite major advances in HIV-1 therapeutics and prevention strategies, the development of a safe and effective prophylactic HIV-1 vaccine will likely be critical for ending the global HIV-1 epidemic. Yet only four HIV-1 vaccine concepts have been tested for clinical efficacy over the past 30 years. In this Commentary, we describe key hurdles facing the HIV-1 vaccine development field and outline strategies to accelerate efficacy evaluation of novel HIV-1 vaccine candidates.

Original language	English
Pages (from-to)	969-972
Number of pages	4
Journal	Cell
Volume	159
Issue number	5
DOIs	https://doi.org/10.1016/j.cell.2014.10.046
State	Published - 20 Nov 2014
Externally published	Yes

Access to Document

10.1016/j.cell.2014.10.046

Cite this

@article{816b0aaa64134f7d993c7a1031688743,

title = "Accelerating HIV-1 vaccine efficacy trials",

abstract = "Despite major advances in HIV-1 therapeutics and prevention strategies, the development of a safe and effective prophylactic HIV-1 vaccine will likely be critical for ending the global HIV-1 epidemic. Yet only four HIV-1 vaccine concepts have been tested for clinical efficacy over the past 30 years. In this Commentary, we describe key hurdles facing the HIV-1 vaccine development field and outline strategies to accelerate efficacy evaluation of novel HIV-1 vaccine candidates.",

author = "Barouch, {Dan H.} and Michael, {Nelson L.}",

year = "2014",

month = nov,

day = "20",

doi = "10.1016/j.cell.2014.10.046",

language = "English",

volume = "159",

pages = "969--972",

journal = "Cell",

issn = "0092-8674",

number = "5",

}

TY - JOUR

T1 - Accelerating HIV-1 vaccine efficacy trials

AU - Barouch, Dan H.

AU - Michael, Nelson L.

PY - 2014/11/20

Y1 - 2014/11/20

N2 - Despite major advances in HIV-1 therapeutics and prevention strategies, the development of a safe and effective prophylactic HIV-1 vaccine will likely be critical for ending the global HIV-1 epidemic. Yet only four HIV-1 vaccine concepts have been tested for clinical efficacy over the past 30 years. In this Commentary, we describe key hurdles facing the HIV-1 vaccine development field and outline strategies to accelerate efficacy evaluation of novel HIV-1 vaccine candidates.

AB - Despite major advances in HIV-1 therapeutics and prevention strategies, the development of a safe and effective prophylactic HIV-1 vaccine will likely be critical for ending the global HIV-1 epidemic. Yet only four HIV-1 vaccine concepts have been tested for clinical efficacy over the past 30 years. In this Commentary, we describe key hurdles facing the HIV-1 vaccine development field and outline strategies to accelerate efficacy evaluation of novel HIV-1 vaccine candidates.

UR - http://www.scopus.com/inward/record.url?scp=84911499033&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2014.10.046

DO - 10.1016/j.cell.2014.10.046

M3 - Comment/debate

C2 - 25416935

AN - SCOPUS:84911499033

SN - 0092-8674

VL - 159

SP - 969

EP - 972

JO - Cell

JF - Cell

IS - 5

ER -

Accelerating HIV-1 vaccine efficacy trials

Abstract

Access to Document

Fingerprint

Cite this